Suppr超能文献

格雷夫斯病患者的B细胞异常表达胰岛素样生长因子-1受体:对疾病发病机制的影响。

B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis.

作者信息

Douglas Raymond S, Naik Vibharavi, Hwang Catherine J, Afifiyan Nikoo F, Gianoukakis Andrew G, Sand Daniel, Kamat Shweta, Smith Terry J

机构信息

Division of Molecular Medicine, Department of Medicine, Harbor-UCLA Medical Center, Torrance, CA 90502, USA.

出版信息

J Immunol. 2008 Oct 15;181(8):5768-74. doi: 10.4049/jimmunol.181.8.5768.

Abstract

Graves' disease (GD) is an autoimmune process involving the thyroid and connective tissues in the orbit and pretibial skin. Activating anti-thyrotropin receptor Abs are responsible for hyperthyroidism in GD. However, neither these autoAbs nor the receptor they are directed against have been convincingly implicated in the connective tissue manifestations. Insulin-like growth factor-1 receptor (IGF-1R)-bearing fibroblasts overpopulate connective tissues in GD and when ligated with IgGs from these patients, express the T cell chemoattractants, IL-16, and RANTES. Disproportionately large fractions of peripheral blood T cells also express IGF-1R in patients with GD and may account, at least in part, for expansion of IGF-1R(+) memory T cells. We now report a similarly skewed B cell population exhibiting the IGF-1R(+) phenotype from the blood, orbit, and bone marrow of patients with GD. This expression profile exhibits durability in culture and is maintained or increased with CpG activation. Moreover, IGF-1R(+) B cells produce pathogenic Abs against the thyrotropin receptor. In lymphocytes from patients with GD, IGF-1 enhanced IgG production (p < 0.05) and increased B cell expansion (p < 0.02) in vitro while those from control donors failed to respond. These findings suggest a potentially important role for IGF-1R display by B lymphocytes in patients with GD in supporting their expansion and abnormal Ig production.

摘要

格雷夫斯病(GD)是一种自身免疫性疾病,累及甲状腺以及眼眶和胫前皮肤的结缔组织。激活型抗促甲状腺素受体抗体导致GD患者出现甲状腺功能亢进。然而,无论是这些自身抗体还是它们所针对的受体,都没有确凿证据表明与结缔组织表现有关。携带胰岛素样生长因子-1受体(IGF-1R)的成纤维细胞在GD患者的结缔组织中过度增殖,当与这些患者的免疫球蛋白G(IgG)结合时,会表达T细胞趋化因子白细胞介素-16(IL-16)和调节激活正常T细胞表达和分泌的因子(RANTES)。GD患者外周血中很大一部分T细胞也表达IGF-1R,这可能至少部分解释了IGF-1R阳性记忆T细胞的扩增。我们现在报告,在GD患者的血液、眼眶和骨髓中,存在同样呈现IGF-1R阳性表型的偏向性B细胞群体。这种表达谱在培养中具有稳定性,并且在CpG激活后得以维持或增加。此外,IGF-1R阳性B细胞会产生针对促甲状腺素受体的致病性抗体。在GD患者的淋巴细胞中,IGF-1在体外增强了IgG的产生(p<0.05)并增加了B细胞的扩增(p<0.02),而来自对照供体的淋巴细胞则无反应。这些发现表明,GD患者B淋巴细胞上的IGF-1R表达在支持其扩增和异常Ig产生方面可能发挥重要作用。

相似文献

6
Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy.
J Endocrinol Invest. 2019 Apr;42(4):471-480. doi: 10.1007/s40618-018-0943-8. Epub 2018 Aug 21.
7
Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy.
Best Pract Res Clin Endocrinol Metab. 2012 Jun;26(3):291-302. doi: 10.1016/j.beem.2011.10.002.
8
Cytokines as Targets of Novel Therapies for Graves' Ophthalmopathy.
Front Endocrinol (Lausanne). 2021 Apr 16;12:654473. doi: 10.3389/fendo.2021.654473. eCollection 2021.
9
Nuclear targeting of IGF-1 receptor in orbital fibroblasts from Graves' disease: apparent role of ADAM17.
PLoS One. 2012;7(4):e34173. doi: 10.1371/journal.pone.0034173. Epub 2012 Apr 10.

引用本文的文献

1
Teprotumumab for treating active thyroid eye disease: A meta-analysis.
Medicine (Baltimore). 2025 Jun 27;104(26):e42966. doi: 10.1097/MD.0000000000042966.
2
The Use of Biologics for Thyroid Eye Disease.
BioDrugs. 2025 Jun 6. doi: 10.1007/s40259-025-00726-0.
3
Teprotumumab Improves Quality of Life in Thyroid Eye Disease: Meta-analysis and Matching-adjusted Indirect Comparison.
J Endocr Soc. 2025 Apr 8;9(6):bvaf063. doi: 10.1210/jendso/bvaf063. eCollection 2025 Jun.
4
A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients.
Lancet Reg Health West Pac. 2025 Jan 18;55:101464. doi: 10.1016/j.lanwpc.2025.101464. eCollection 2025 Feb.
5
Novel perspectives on the pharmacological treatment of thyroid-associated ophthalmopathy.
Front Endocrinol (Lausanne). 2025 Jan 13;15:1469268. doi: 10.3389/fendo.2024.1469268. eCollection 2024.
6
Teprotumumab versus intravenous methylprednisolone in thyroid eye disease: A systematic review.
Oman J Ophthalmol. 2024 Oct 24;17(3):313-319. doi: 10.4103/ojo.ojo_308_23. eCollection 2024 Sep-Dec.
7
Graves disease: latest understanding of pathogenesis and treatment options.
Nat Rev Endocrinol. 2024 Nov;20(11):647-660. doi: 10.1038/s41574-024-01016-5. Epub 2024 Jul 22.
9
The changing landscape of thyroid eye disease: current clinical advances and future outlook.
Eye (Lond). 2024 Jun;38(8):1425-1437. doi: 10.1038/s41433-024-02967-9. Epub 2024 Feb 19.
10
Fibrocyte Participation in Thyroid-Associated Ophthalmopathy Suggests New Approaches to Therapy.
Ophthalmic Plast Reconstr Surg. 2023 Dec 1;39(6S):S9-S18. doi: 10.1097/IOP.0000000000002509. Epub 2023 Dec 4.

本文引用的文献

4
Phosphatidylinositol 3-kinase (PI3K) signaling and regulation of the antibody response.
Cell Cycle. 2007 Feb 15;6(4):397-402. doi: 10.4161/cc.6.4.3837. Epub 2007 Feb 9.
6
Immunopathologic role of B lymphocytes in rheumatoid arthritis: rationale of B cell-directed therapy.
Autoimmun Rev. 2006 Aug;5(7):437-42. doi: 10.1016/j.autrev.2006.02.004. Epub 2006 Mar 9.
7
IGF-I mediated survival pathways in normal and malignant cells.
Biochim Biophys Acta. 2006 Aug;1766(1):1-22. doi: 10.1016/j.bbcan.2006.05.003. Epub 2006 Jun 7.
8
Insulin/IGF signalling in neurogenesis.
Cell Mol Life Sci. 2006 Aug;63(15):1701-5. doi: 10.1007/s00018-006-6036-4.
9
Signalling pathways in B cells: implications for autoimmunity.
Curr Top Microbiol Immunol. 2006;305:213-40. doi: 10.1007/3-540-29714-6_11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验